Valuation: SIMULATIONS PLUS

Market Cap 371M 321M 301M 274M 515M 35.49B 524M 3.53B 1.38B 17.77B 1.39B 1.36B 59.06B P/E 2026 *
43.7x
P/E 2027 * 40.1x
Enterprise Value 371M 321M 301M 274M 515M 35.49B 524M 3.53B 1.38B 17.77B 1.39B 1.36B 59.06B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 4.3x
Free-Float
83.09%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Change 5-day change 1-year change 3-year change Capi.($)
-3.52%+5.76%-13.14%+27.47% 39.6B
-2.64%+1.58%-42.95%+146.67% 13.25B
+1.72%+5.91%-18.62%+77.11% 5.74B
+35.70%+46.01%+35.00% - 3.66B
+4.06%+8.99% - - 2.01B
-0.90%+1.33%+17.70%-42.33% 1.7B
-3.16%-5.28%-40.41% - 967M
+1.97%+0.86%+38.78%+134.67% 924M
-0.82%+0.28%-32.47%-47.25% 836M
Average +3.60%+3.99%-7.01%+49.39% 7.63B
Weighted average by Cap. -0.42%+5.39%-16.02%+56.19%

Financials

2026 *2027 *
Net sales 81.87M 70.71M 66.45M 60.43M 114M 7.83B 115M 779M 304M 3.92B 307M 301M 13.03B 86.26M 74.5M 70.01M 63.67M 120M 8.25B 122M 820M 321M 4.13B 324M 317M 13.73B
Net income 9.53M 8.23M 7.74M 7.04M 13.23M 912M 13.45M 90.66M 35.45M 457M 35.79M 35.02M 1.52B 10.18M 8.79M 8.26M 7.51M 14.13M 974M 14.36M 96.82M 37.86M 488M 38.23M 37.4M 1.62B
Net Debt - -
Logo SIMULATIONS PLUS
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B